Pavmed ( (PAVM) ) has released its Q3 earnings. Here is a breakdown of the information Pavmed presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Pavmed Inc. is a life sciences company focused on developing and commercializing innovative healthcare technologies, particularly in the medical device and diagnostics sectors. The company operates through subsidiaries, including Lucid Diagnostics and Veris Health, targeting unmet medical needs with substantial market opportunities.
In its latest earnings report, Pavmed Inc. reported a net loss attributable to common stockholders of approximately $1.9 million for the nine months ending September 30, 2025. The company experienced a significant decrease in revenue compared to the previous year, with total revenue for the nine months at $19,000, down from $2.985 million in the same period of 2024.
Key financial highlights include a reduction in operating expenses from $42.3 million in the first nine months of 2024 to $15 million in the same period of 2025. The company also reported a significant decrease in its Senior Secured Convertible Notes liability, from $29.1 million at the end of 2024 to $6.9 million by September 2025, reflecting efforts to manage its debt obligations.
Looking ahead, Pavmed’s management remains focused on expanding its flagship product, EsoGuard, and pursuing strategic partnerships to enhance the Veris Cancer Care Platform. The company acknowledges the challenges posed by its current financial position, including a working capital deficiency, and plans to explore additional capital raising opportunities to support its operations and growth initiatives.